BAM
AUPH icon

Belpointe Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Belpointe Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-221
Closed -$2.42K – 787
2023
Q1 		$2.42K Hold
221
– – ﹤0.01% 3259
2022
Q4 		$955 Buy
+221
New +$1.28K ﹤0.01% 3448

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Belpointe Asset Management's AUPH Position: Q2 2023 in Review

Belpointe Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2023, closing a stake of 221 shares — an estimated $2.42K sold.

Belpointe Asset Management first reported a position in AUPH in Q4 2022 and held it in 2 quarters. The position peaked at $2.42K in Q1 2023. 200 funds tracked by Wall St. Rank hold AUPH as of Q2 2023.

  • Belpointe Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 221 Aurinia Pharmaceuticals shares in Q2 2023, an estimated $2.42K.
  • Belpointe Asset Management first reported a position in Aurinia Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Aurinia Pharmaceuticals position peaked at $2.42K in Q1 2023.
  • 200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.